C.R. Bard, a Dividend Aristocrat, Is a Great Long-term Investment

The multi-year price upside chart of C. R. Bard (BCR), a medical device maker, tells the story of its success as a worldwide provider of medical products and services for surgery and disease management in vascular, urology and oncology.

Since February, 1984 BCR has compiled a 17.74 percent annualized return. In addition, Bard has a long, interrupted record of paying rising dividends, making it a member of the exclusive Dividend Aristocrats.

Aflac is a candidate for a long-term dividend reinvestment portfolio.